To determine the prognostic value of the albumin–bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma
Gastroenterology and Hepatology from Bed to Bench,
Vol. 12 No. 2 (2019),
18 March 2019
,
Page 110-115
https://doi.org/10.22037/ghfbb.v12i2.1487
Abstract
Aim: We aimed at determining the prognostic value of the albumin–bilirubin grade (ALBI) in patients undergoing transarterial Chemoembolization for unresectable Hepatocellular carcinoma.
Background: Various noninvasive liver reserve markers are used to predict the severity of liver injury. The role and probability of these markers in predicting the prognosis of patients with hepatocellular carcinoma (HCC) is still unknown.
Methods: Patients who underwent TACE from 2013 to 2017 were included. Patient’s age, gender, cause of cirrhosis, ALBI Grade along with the site, size and number of tumors were recorded. Radiological response to TACE was assessed by CT scan at 1 and 3 months after the procedure, respectively. Survival assessment was performed and all patients were assessed for survival until the last follow-up.
Results: A total of 71 patients were included. Majority of them were male (80.3 %). The mean tumor size of 6 ± 3.9 cm. Majority of patients (54.9 %) had a single lesion and it was mostly localized to the right lobe (60.5 %). The most common cause of chronic liver disease was HCV (65.3%). Median Child class score (CTP) and MELD score were 7 and 10, respectively. Ascites was treated prior to TACE in 12 patients (16.9 %).
Mean ALBI score in the study population was -1.59 ± 0.69, with the majority (49. 2 %) falling in grade 2. The mean duration of survival at the last follow up was of 12.1 ± 12.14 months (1- 49).
Univariate analysis showed serum albumin (p = 0.003), serum bilirubin (p = 0.018), CTP score (p = 0.019), ALBI grade (p = 0.001) and presence of varices (p = 0.04) to be the main predictors of 6 months survival after TACE. On Cox analysis, only ALBI score (p = 0.038) showed statistical significant association.
Conclusion: ALBI grade may serve as a surrogate marker in predicting the prognosis of HCC patients undergoing Transarterial Chemoembolization.
Keywords: Hepatocellular carcinoma, Unresectable disease, Transarterial chemoemobolization, ALBI grade, CTP score, MELD score.
(Please cite as: Khalid MA, Achakzai IK, Hanif FM, Ahmed SH, Majid Z, Luck NH. To determine the prognostic value of the albumin–bilirubin grade (albi) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma. Gastroenterol Hepatol Bed Bench 2019;12(2):110-115).
- HCC
- ALBI score
- TACE
How to Cite
References
El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
Badar F, Mahmood S. Hospital-based cancer profile at the Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, pakistan. J Coll Physicians Surg Pak 2015;25:259-63.
Bhurgri Y, Bhurgri A, Hassan SH, Zaidi SH, Rahim A, Sankaranarayanan R, et al. Cancer incidence in Karachi, Pakistan: first results from Karachi Cancer Registry. Int J Cancer 2000;85:325-9.
Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatol 2013;58:546-54.
Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinomaÐepidemiological trends and risk factors. Dig Dis 2009; 27:80-92.
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatol 2005;42:1208-36.
Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8.
Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002;359:1734-9.
Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatol 2002;35:1164-71.
Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28.
Forner A, Reig ME, De Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61–74.
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatol 1998;28:751–5.
Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatol 2000;32:1224-9.
Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 2005;100:1764-71.
Okajima C, Arii S, Tanaka S, Matsumura S, Ban D, Ochiai T, et al. Prognostic role of Child-Pugh score 5 and 6 in hepatocellular carcinoma patients who underwent curative hepatic resection. Am J Surg 2015;209:199-205.
Franco D, Capussotti L, Smadja C, Bouzari H, Meakins J, Kemeny F, et al. Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterol 1990;98:733-8.
Seyama Y, Kokudo N. Assessment of liver function for safe hepatic resection. Hepatol Res 2009;39:107–16.
Hung HH, Chao Y, Chiou YY, Li CP, Lee RC, Huo TI, et al. A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6. Medicine 2014;93:e348.
Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterol 2012;142:1293-302.
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550-8.
Abbas Z, Siddiqui AU, Luck NH, Hassan M, Mirza R, Naqvi A, et al. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. J Pak Med Assoc 2008;58:602-7.
Llovet JM, Bruix J. Systematic review of randomize trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatol 2003;37:429-42.
De Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol 2012;56:S75–87.
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatol 1998;28:751-5.
Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2016;31:1031-6.
Ho SY, Liu PH, Hsu CY, Hsia CY, Lee YH, Lee RC, et al. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Plos One 2017;12:e0180408.
- Abstract Viewed: 103 times
- PDF Downloaded: 77 times